An oncological view on the blood-testis barrier

Lancet Oncology

Volumn 3, Issue 6, 2002, Pages 357-363

  Bart, Joost ^a   Groen, Harry JM ^a   Van Der Graaf, Winette TA ^a   Hollema, Harry ^a   Hendrikse, N Harry ^a   Vaalburg, Willem ^a   Sleijfer, Dirk T ^a   De Vries, Elisabeth GE ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BASIC FIBROBLAST GROWTH FACTOR; BILIRUBIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DIGOXIN; DRUG; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE TRANSPORTER 1; GLYCOPROTEIN P; HORMONE; IFOSFAMIDE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; XENOBIOTIC AGENT;

ADULT; ANIMAL CELL; ANIMAL TISSUE; AZOOSPERMIA; BLOOD TESTIS BARRIER; CAPILLARY ENDOTHELIUM; CONTROLLED STUDY; DRUG DISTRIBUTION; GERM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; LEUKEMIA; MALE; MALE FERTILITY; MOUSE; NONHUMAN; OLIGOSPERMIA; ONCOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REVIEW; SEMINIFEROUS TUBULE; SERTOLI CELL; TIGHT JUNCTION;

EID: 0036075392     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(02)00776-3     Document Type: Review

References (75)

1. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: Results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991)
2. Relapse after first cessation of therapy in childhood acute lymphoblastic leukemia: A 10-year follow-up study
3. Testicular lymphoma: Late relapses and poor outcome despite doxorubicin-based therapy
4. Diffuse large-cell lymphoma of the testis
5. Cisplatin-based chemotherapy changes the incidence of bilateral testicular cancer
6. Effect of chemotherapy on carcinoma in situ of the testis
7. Testis conservation studies in germ cell cancer justified by improved primary chemotherapy response and reduced delay, 1978-1994
8. Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated?
9. Current opinion in germ cell cancer 2000
10. Fertility after chemotherapy for testicular germ cell cancers
11. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer
12. Effect of treatment on fertility and sexual function in males with metastatic nonseminomatous germ cell tumors of testis
13. Fertility after chemotherapy for testicular germ cell cancer
14. Immunocompetent cells in human testis in health and disease
15. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study
16. The blood-testis barrier in the rat and the physiological compartmentation of the seminiferous epithelium
17. Observations on the inter-relationships of Sertoli cells at the level of the blood-testis barrier: Evidence for formation and resorption of Sertoli-Sertoli tubulobulbar complexes during the spermatogenetic cycle of the rat
18. Functional cytology of the human testis
19. The blood-testis barrier and Sertoli cell junctions: Structural considerations
20. Barrier properties of testis microvessels
21. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: A study using quail-chick transplantation chimeras
22. Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors
23. Response of the seminiferous epithelium of the rat testis to withdrawal of androgen: Evidence for direct effect upon intercellular spaces associated with Sertoli cell junctional complexes
24. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice
25. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
26. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
27. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
28. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex
29. Mechanism of action of P-glycoprotein in relation to passive membrane permeation
30. ABC transporters: From microorganisms to man
31. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
32. Frequency of C3435T polymorphism of MDR1 gene in African people
33. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
34. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
35. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations
36. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues: Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule
37. Multidrug resistance gene family and chemical carcinogens
38. The blood-brain barrier and oncology: New insights into function and modulation
39. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines
40. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16
41. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines
42. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells
43. MRP3, an organic anion transporter able to transport anti-cancer drugs
44. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells
45. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake
46. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells
47. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells
48. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier
49. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA
50. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier
51. Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance
52. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage
53. Death receptors: Signaling and modulation
54. A role for CD95 ligand in preventing graft rejection
55. Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes
56. Fas regulates germ cell apoptosis in the human testis in vitro
57. The Fas system is a key regulator of germ cell apoptosis in the testis
58. Fas and Fas ligand expression in fetal and adult human testis with normal or deranged spermatogenesis
59. Testicular FasL is expressed by sperm cells
60. Immunohistochemical characterization of seminoma and its inflammatory cell infiltrate
61. Burned-out primary testicular cancer: Sonographic and pathological characteristics
62. Metastatic seminoma with regression of testicular primary: Ultrasonographic detection
63. Pulmonary metastasis secondary to burned-out testicular tumor
64. Burned-out tumour of the testis presenting as retroperitoneal choriocarcinoma
65. In situ observation of inflammatory cell-tumor cell interaction in human seminomas (germinomas): Light, electron microscopic, and immunohistochemical study
66. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: Evidence for the existence of an immunological brain barrier
67. P-glycoprotein function of the blood-brain barrier in humans can be measured with positron emission tomography
68. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
69. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier
70. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)
71. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukamia (AML) patients 60 years (CALGB 9720)
72. Modulation of multidrug resistance (MDR) in hematological malignancies
73. Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma
74. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualised with positron emission tomography
75. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A